

Supplementary Content

Methods

References

Table 1. Definition of variables in UK Biobank

Table 2. Definition of Coronary Artery Disease (CAD)

Table 3. Descriptive Characteristics

Table 4. Association of Different Polygenic Risk Scores (PRS) With Coronary Artery Disease (CAD) in Tuning Case-Control and Prospective Cohort Study

Table 5. C Statistics (Derived for Cox Regression) for CAD Using Recalibrated Models in the PCE Prospective Cohort.

Table 6. Risk Reclassification at 7.5% Threshold for CAD Using Recalibrated PCE and PCE + PRS Models Stratified by Gender and Age Group (below or above 55 years of age)

Table 7. Net Reclassification Improvement and Integrated Discrimination Improvement Results in Secondary Analysis of 6,753 African Ancestry Participants

Figure 1. Correlation of PRSs Constructed by Different Methods in the Tuning Set of 9,499 Prevalent CAD cases and an Equal Number of Controls

Figure 2. Calibration and Recalibration Plots Polygenic Risk Score for Coronary Artery Disease (CAD) and PRS Combined with PCE, Using a UK Biobank Prospective Cohort Sample

Methods

Variables included in PCE

Smoking status was based on self-reported information on current smoking status (“most or all days” and “occasional” smokers), previous smoking status and non-smoking status (previous and non-smoking are coded as non-smokers in PCE). Smoking status was determined to be missing when participant’s answer to the nurse administered questionnaires was “Prefer not to answer.” Mean systolic blood pressure was calculated from two measurements taken seated using an appropriate cuff and an Omron HEM-7015IT digital BP monitor or a manual reading.³ In cases where digital BP measurement was not available, the manual measurement was utilized. We defined medication status based on nurse administered questionnaires on blood pressure lowering and lipid lowering medications. Serum data was corrected for laboratory dilution effects and excluded if they fell outside the defined UK Biobank specifications.⁴ Total serum cholesterol and HDL cholesterol were obtained via enzymatic assays.⁴ We calculated their ratio and corrected total and HDL cholesterol for individuals on lipid-lowering medication by dividing total cholesterol by 0.73 and HDL cholesterol by 1.03.⁵

Information on prevalent disease was obtained from nurse administered questionnaires as well as from relevant International Classification of Disease (ICD) or Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures (OPCS-4) codes. These were obtained from in hospital episode statistics (HES) data with a date of event preceding the date of assessment center attendance. Type 1 and 2 diabetes were defined by self-reported diagnoses or from ICD codes in HES data prior to assessment date. In addition, type 2 diabetes was defined by self-reported medications and HbA1c measurements at baseline ≥ 48 mmol/mol. All variables are defined based on ICD-9, ICD-10, OPCS-4, and relevant UK Biobank field codes as shown in Table 1 of the Supplementary.

Calculation of Polygenic Risk Scores (PRS)

A PRS is calculated as the weighted sum of an individual’s risk alleles. Several factors need to be considered during PRS calculations including (i) the weights used for each SNP, (ii) the number of SNPs included in each score, and (iii) the method to account for correlations between SNPs (linkage disequilibrium [LD]).

We looked at seven methods for PRS calculation that approach these concerns differently:

1. Clumping and Thresholding⁶ (P + T) – This method is commonly used and estimates SNP effects from the largest GWAS as the SNP weights. LD is accounted for by a clumping algorithm, which produces a subset of independent SNPs while selecting those with the strongest association to the desired phenotype. The number of SNPs in the subset included in the PRS is selected by applying a P-value threshold to the original GWAS dataset. Typically, calculations are done with multiple P-value thresholds, and in some cases multiple clumping parameters, to maximize the ability of the PRS to predict the desired target phenotype. Polygenic risk scores were calculated over a range of r^2 thresholds (0.2, 0.4, 0.6, 0.8) and P values (1, 0.5, 0.05, 5e-4, 5e-6, 5e-8).
2. LDpred⁷ – The LDpred algorithm uses a Bayesian approach to generate posterior mean effects for each SNP included in the GWAS by conditioning on a genetic prior of effects and LD information from an external reference panel. 1000 Genome Project Phase 3 LD reference panels for each population were used. Only the HapMap3 subset of SNPs were used in the tuning of this method. The prior includes two parameters that need to be explored: the heritability explained by the genotype, which is estimated from the GWAS and accounts for sampling noise and LD, and the fraction of causal markers (the fraction of genetic markers with non-zero effects). A LD radius is also required, indicating the number of SNPs adjusted for on each side of a given SNP. In this study, the LD radius was set to 267 and the fraction of causal markers were examined at $p = (1, 0.1, 0.3, 1e-2, 3e-2, 1e-3, 3e-3)$. Like P+T, multiple fractions of causal markers are investigated to optimize the predictive accuracy of the PRS. LD is approximated using an external reference panel that is specific to ancestry of the GWAS dataset.

3. Lassosum⁸ - Lassosum aims to achieve maximum predictive accuracy in similar fashion to LDpred, by optimizing SNP weights and accounting for LD. Lassosum performs this by using a penalized regression model to carry out shrinkage and the selection of SNPs from the GWAS dataset, while using the same external LD reference panel as LDpred. Two model parameters (s and λ) are set, with the PRS being calculated over a grid of s and λ values in order to maximize phenotypic prediction. For CAD, lassosum has been shown to perform similar to or better than LDpred.^{7,8} LD reference panels for each GWAS dataset were defined previously and used as recommended by the author.⁹ Reference panels were also set to the hg19 genome.
4. PRS-CS¹⁰ - This method is another method that utilizes a high-dimensional Bayesian framework to infer posterior effect sizes of SNPs using genetic prior effect sizes and an external LD reference panel. In contrast to other methods developed, PRS-CS places a continuous shrinkage (CS) prior on SNP effect sizes. This allows for marker-specific adaptive shrinkage (shrinkage on each genetic marker is adaptive to the strength of the association signal in GWAS) and is more robust to different genetic architectures. PRS-CS is also more accurate in modeling local LD patterns. In simulation, PRS-CS has been shown to outperform LDpred, especially as training sample size increases.¹⁰ For CAD, PRS-CS has demonstrated similar predictive accuracy to LDpred. For our study, the European (EUR) and East Asian (EAS) superpopulation LD reference panels constructed using 1000 Genome Project Phase 3 samples provided by the author were implemented. The European meta-analysis dataset used the EUR LD reference panel, and the Biobank Japan dataset used the EAS reference panel. The polygenic risk scores were calculated using four levels of global shrinkage parameter $\phi = (1e-6, 1e-4, 1e-2, 1)$ in order to find the optimal ϕ value during validation.
5. sBayesR¹¹ - Another method that infers posterior mean effect sizes from a GWAS dataset and a LD matrix. This method assumes a finite number of normal distributions to account for sparsity with probabilities ranging from 1 to C , the number of components in the mixture model. The recommended parameters for this method are to set $C = 4$ with parameters $\gamma_c = (0, 0.01, 0.1, 1)$, indicating the scaling factor for the mixture component variance. C was set to 0.95, 0.02, 0.02, and 0.01 in our analysis. This method also requires a shrunk LD matrix, which has been provided by the author. Two different matrices were made available: a 1.1M SNP set constructed by restricting 1,365,446 SNPs from HapMap3 to $MAF > 0.01$ and a 2.8M SNP set constructed by applying LD-pruning to a larger 8 million variant set from the UK Biobank to $MAF > 0.01$.
6. LDpred-funct¹² - This method is a modified version of LDpred-funct-inf, which itself is a modification of LDpred-inf. LDpred-funct-inf extends LDpred-inf to incorporate functionally informed priors on causal effect sizes using the baseline-LD model.¹³ The 1000 Genome Project Phase 3 derived baseline-LD models (v1.1) containing 75 functional annotations estimated by stratified LD score regression was used for both the European meta-analysis and Japan Biobank datasets. The corresponding EUR and EAS frequency files and HapMap3 subset derived weights were likewise used in the tuning of this method. Each trait is used to determine the per-SNP heritability under the baseline-LD model. LDpred-funct further modifies this method by using cross-validation to regularize posterior mean causal effect sizes. SNPs are ranked by their absolute posterior effect sizes and partitioned into K bins. The relative weights of each bin are determined based on their predictive value in the validation dataset. This non-parametric shrinkage allows LDpred-funct to optimize predictive accuracy regardless of the underlying genetic architecture.
7. DBSLMM¹⁴ - Deterministic Bayesian Sparse Linear Mixed Model (DBSLMM) is a method designed to create a scalable PRS method that is computationally less intensive and thus can be used for larger GWAS datasets efficiently. This method relies on the same effect size distribution assumption made in the BSLMM method. A major difference between these two methods is the use of Markov chain Monte Carlo (MCMC) for posterior sampling in BSLMM, leading it to be computationally slow especially as GWAS size increases. DBSLMM instead utilizes a searching algorithm to subset SNPs with potential large effect sizes. Small effect size SNPs are combined to find total effect size. Both subsets are then combined with a block-diagonal SNP correlation matrix. This leads to DBSLMM having a computationally complexity approximately linear respective to both sample size and the number of SNPs. We tuned this method using the EUR and EAS region reference LD panels in a similar manner as other methods. The recommended block information used in the

derivation of the polygenic risk scores was obtained from a previously published study.⁷ We tested DBSLMM at three folds of heritability levels: 0.8, 1.0, and 1.2, respectively.

Reclassification Metrics

We calculated the net reclassification index (NRI) at the current recommended threshold for treatment in the US (7.5%). The associated category-free NRI and integrated discrimination improvement (IDI) were also calculated. The NRI is calculated for nested models, PCE vs PCE + PRS in our study, using a 2x2 classification table at the defined threshold. “Upward” movement in categories is defined as subjects with a better outcome after reclassification while “downward” movement is defined as subjects with a worse reclassification. The improvement in reclassification is calculated as the sum of the differences in proportions in subjects moving up minus those moving down that had an event/outcome, and the proportion of subjects moving down minus those moving up that did not experience the outcome.¹⁵ NRI has been shown to be sensitive to the number and choices of thresholds¹⁶, and as such the category-free (continuous) NRI has been proposed. The continuous NRI is calculated as the relative increase in the predictive probabilities of subjects that experience the event and the decrease in those who do not.¹⁷ IDI is defined as a measure that integrates the NRI over all possible cut-offs for the probability of the outcome. The IDI is equivalent to the difference in the discrimination slopes between 2 models.¹⁵

References

1. Wang Y, Guo J, Ni G, et al. Theoretical and empirical quantification of the accuracy of polygenic scores in ancestry divergent populations. *Nature Communications*. 2020; 11:3865.
2. Backman J, Li A, Marcketta A, et al. Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature*. 2021; 599:628-634.
3. UK Biobank Coordinating Centre; UK Biobank: Protocol for a large-scale prospective epidemiological resource. 2007; <http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf>.
4. UK Biobank. Biomarker assay quality procedures: approaches used to minimize systematic and random errors (and the wider epidemiological implications). 2019; https://biobank.ctsu.ox.ac.uk/showcase/docs/biomarker_issues.pdf.
5. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med*. 2005; 352(1):29-38.
6. Choi SW, Mak TS, O'Reily PF. Tutorial: a guide to performing polygenic risk score analyses. *Nature Protocols*. 2020; 15:2759-2772.
7. Vilhjalmsón BJ, Yang J, Finucane HK, et al. Modeling Linkage Disequilibrium Increase Accuracy of Polygenic Risk Scores. *Am J Hum Genet*. 2015; 97(4):576-592.
8. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized regression on summary statistics. *Genetic epidemiology*. 2017; 41(6):469-480.
9. Berisa T and Pickrell J. Approximately independent linkage disequilibrium blocks in human populations. *Bioinformatics*. 2016, 32(2):283-285.
10. Ge T, Chen CY, Fang YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature Communications*. 2019; 10(1):1776.
11. Lloyd-Jones LR, Zeng J, Sidorenko J, et al. Improved polygenic prediction by Bayesian multiple regression on summary statistics. *Nature Communications*. 2019; 10:5086.
12. Márquez-Luna C, Gazal S, Loh P, et al. LDpred-funct: incorporating functional priors improves polygenic prediction accuracy in UK Biobank and 23andMe data sets. *BioRxiv*. 2018; doi: <https://doi.org/10.1101/375337>.
13. Gazal S, Finucane H, Furlotte A, et al. Linkage disequilibrium-dependent architecture of human complex traits shows action of negative selection. *Nature Genetics*. 2017; 49:1421 EP-,09.
14. Sheng Y, Zhou X. Accurate and Scalable Construction of Polygenic Scores in Large Biobank Data Sets. *Am J Hum Genet*. 2020; 106(5):679-693.
15. Goodard M, et al. In: Balding D, Moltke I, Marioni J, editors. *Handbook of Statistical Genomics*. 4 ed. Hoboken, USA: John Wiley and Sons; 2019; p. 799-20.
16. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010; 21(1):128-138.
17. Tzoulaki I, Liberopoulos G, Ioannidis JP. Use of reclassification for assessment of improved prediction: an empirical evaluation. *International journal of epidemiology*. 2011; 40(4):1094-1105.

Table 1. Definition of Variables in UK Biobank

	HES statistics ICD-10 and ICD-9 codes (with date of event < date of visit)	Self-reported Data-field 20002	Treatment and medication code Data-Field 20003	Other data fields
Type 1 diabetes	ICD-10 E10, O230; ICD-9 25001, 25011, 25021, 25031, 25041, 25051, 25061, 25071, 25081, 25091, 25003, 25013, 25023, 25033, 25043, 25053, 25063, 25073, 25083, 25093	1222		
Type 2 diabetes	ICD-10 E11, O231; ICD-9 25000, 25010, 25020, 25030, 25040, 25050, 25060, 25070, 25080, 25090, 25002, 25012, 25022, 25032, 25042, 25052, 25062, 25072, 25082, 25092	1223, 1220	1140868902, 1140874646, 1140874674, 1140874718, 1140874744, 1140883066, 1140884600, 1141152590, 1141157284, 1141168660, 1141171646, 1141173882, 1141189090	Biobank field 2443 = 1; HbA1c measurement ≥ 48 mmol/mol
Lipid lowering medication			1140861954, 1140861958, 1140888594, 1140888648, 1141146234, 1141192410, 1141192736	
Blood pressure lowering medication			1140860192, 1140860292, 1140860696, 1140860728, 1140860750, 1140860806, 1140860882, 1140860904, 1140861088, 1140861190, 1140861276, 1140866072, 1140866078, 1140866090, 1140866102, 1140866108, 1140866122, 1140866138, 1140866156, 1140866162, 1140866724, 1140866738, 1140868618, 1140872568, 1140874706, 1140874744, 1140875808, 1140879758, 1140879760, 1140879762, 1140879802, 1140879806, 1140879810, 1140879818, 1140879822, 1140879826, 1140879830, 1140879834, 1140879842, 1140879866, 1140884298, 1140888552, 1140888556, 1140888560, 1140888646, 1140909706, 1140910442, 1140910614, 1140916356, 1140923272, 1140923336, 1140923404, 114923712, 1140926778, 1140928226, 1141145660, 1141146126, 1141152998, 1141153026, 1141164276, 1141165470, 1141166006, 1141169516, 1141171336, 1141180592, 1141180772, 1141180778, 1141184722, 1141193282, 1141194794, 1141194810	Biobank fields 6177, 6153 = 2

Table 2. Definition of Coronary Artery Disease (CAD)

ICD-10	ICD-9	OPCS-4	Non-cancer illness code (Biobank field: 20002)	Operation code (Biobank field: 20004)	Vascular/heart problems diagnosed by doctor (Biobank field: 6150)
I21	410	K40.1-4	1075: Heart attack/myocardial infarction	1070: Coronary angioplasty	1: Heart attack
I22	411	K41.1-4		1095: Coronary artery bypass graft	
I23	412	K45.1-5			
I24.1		K49.1-2			
I25.2		K49.8-9			
		K50.2			
		K75.1-4			
		K75.8-9			

Table 3A. Descriptive Characteristics of Tuning (Case-Control) Set (N=18,998)

	Men	Women
N	12043	6955
Age (years) (mean (SD)) *	60.23 (7.21)	58.16 (7.82)
Mean SBP (mmHg) (mean (SD)) *	137.92 (18.57)	137.62 (18.7)
Smoking category (%) *		
Non-smoker	4652 (38.6)	3857 (55.5)
Ex-smoker	5974 (49.6)	2450 (35.2)
Current smoker	1417 (11.8)	648 (9.3)
Type 1 diabetes (%) *	325 (2.7)	118 (1.7)
Type 2 diabetes (%) *	2621 (21.8)	775 (11.1)
Blood pressure lowering medication (%) *	7877 (65.4)	2503 (36.0)
Cholesterol (mmol/L) (mean (SD)) *	4.82 (1.15)	5.63 (1.18)
HDL cholesterol (mmol/L) (mean (SD)) *	1.2 (0.3)	1.55 (0.38)
Lipid lowering medication (%) *	7230 (60.0)	1886 (27.1)

* Variables used in PCE. Current smokers vs non-current smokers and diabetes as a binary variable

Table 3B. Descriptive Characteristics of PCE Prospective Cohort/Testing Set (N=272,307)

	Full Population		Incident CAD	
	Men	Women	Men	Women
N	124118	148189	5093	1943
Age (years) (Mean (SD))	56.8 (8.09)	56.6 (7.88)	60.44 (6.6)	61.1 (6.46)
Mean SBP (mmHg) (mean (SD))	137.86 (18.66)	137.84 (18.68)	138.32 (18.74)	138.13 (18.45)
Smoking category (%)				
Current	14580 (11.7)	12747 (8.6)	806 (15.8)	325 (16.7)
Non-current	109538 (88.3)	135442 (91.4)	4287 (84.2)	1618 (83.3)
Type 1 Diabetes (%)	1260 (1.0)	1016 (0.7)	150 (2.9)	59 (3.0)
Type 2 Diabetes (%)	12832 (10.3)	8962 (6.0)	1082 (21.2)	345 (17.8)
Blood pressure lowering medication (%)	21506 (17.3)	15629 (10.5)	2220 (43.6)	814 (41.9)
Cholesterol (mmol/L) (mean (SD))	5.57 (1.1)	5.91 (1.12)	5.28 (1.58)	5.71 (1.62)
HDL cholesterol (mmol/L) (mean (SD))	1.29 (0.31)	1.6 (0.38)	1.23 (0.29)	1.49 (0.36)
Person-years of observation (mean (SD))	11.79 (2.27)	12.13 (1.65)	4.82 (2.51)	5.15 (2.5)
Lipid lowering medication (%)	21562 (17.4)	15611 (10.5)	1466 (28.8)	479 (24.7)

Table 3C. Descriptive Characteristics of the PCE Prospective Cohort and Excluded Participants

	Prospective cohort (N = 272307)		Excluded (N = 43474) *		
	Men	Women	Men	Women	Missing counts
N	124118	148189	17790	20084	5600
Age (years) (Mean (SD))	56.8 (8.09)	56.6 (7.88)	57.03 (8.08)	56.65 (7.89)	
Mean SBP (mmHg) (mean (SD))	137.86 (18.66)	137.84 (18.68)	137.84 (18.72)	137.85 (7.89)	633
Smoking category (%)					135
Current	14580 (11.7)	12747 (8.6)	2088 (11.8)	1718 (8.5)	
Non-current	109538 (88.3)	135442 (91.4)	15621 (88.2)	18366 (91.5)	
Type 1 Diabetes (%)	1260 (1.0)	1016 (0.7)	211 (1.2)	161 (0.8)	
Type 2 Diabetes (%)	12832 (10.3)	8962 (6.0)	2026 (11.4)	1257 (6.3)	
Blood pressure lowering medication (%)	21506 (17.3)	15629 (10.5)	5159 (29.1)	4077 (20.3)	
Cholesterol (mmol/L) (mean (SD))	5.57 (1.1)	5.91 (1.12)	5.5 (1.13)	5.89 (1.13)	15553
HDL cholesterol (mmol/L) (mean (SD))	1.29 (0.31)	1.6 (0.38)	1.28 (0.31)	1.6 (0.38)	42489
Person-years of observation (mean (SD))	11.79 (2.27)	12.13 (1.65)	10.39 (6.23)	11.39 (4.53)	
Lipid lowering medication (%)	21562 (17.4)	15611 (10.5)	3776 (21.3)	2285 (11.4)	

* 5600 participants excluded from calculations due to missing variables on gender

Table 3D. Descriptive Characteristics of Tuning (Case-Control) Set, Secondary Analysis (N=218)

	Men	Women
N	111	107
Age (years) (mean (SD)) *	55.3 (8.46)	52.92 (8.17)
Mean SBP (mmHg) (mean (SD)) *	135.09 (18.69)	138.38 (19.36)
Smoking category (%) *		
Non-smoker	56 (50.5)	81 (75.7)
Ex-smoker	32 (28.8)	13 (12.15)
Current smoker	23 (20.7)	13 (12.15)
Type 1 diabetes (%) *	2 (1.8)	5 (4.7)
Type 2 diabetes (%) *	48 (43.2)	38 (35.5)
Blood pressure lowering medication (%) *	70 (63.1)	54 (50.5)
Cholesterol (mmol/L) (mean (SD)) *	4.29 (1.47)	4.56 (1.25)
HDL cholesterol (mmol/L) (mean (SD)) *	1.25 (0.28)	1.5 (0.33)
Lipid lowering medication (%) *	49 (44.1)	36 (33.6)

* Variables used in PCE. Current smokers vs non-current smokers and diabetes as a binary variable

Table 3E. Descriptive Characteristics of PCE Prospective Cohort/Testing Set, Secondary Analysis (N= 6,753)

	Full Population		Incident CAD	
	Men	Women	Men	Women
N	2901	3852	46	42
Age (years) (Mean (SD))	51.26 (8.13)	51.9 (7.93)	55.61 (8.57)	55.4 (8.41)
Mean SBP (mmHg) (mean (SD))	136.87 (18.56)	138.12 (18.59)	136.83 (16.83)	135.08 (20.25)
Smoking category (%)				
Current	481 (16.6)	356 (9.2)	10 (21.7)	6 (14.3)
Non-current	2420 (83.4)	3496 (90.8)	36 (78.3)	36 (85.7)
Type 1 Diabetes (%)	57 (2)	67 (1.7)	7 (15.2)	3 (7.1)
Type 2 Diabetes (%)	606 (20.1)	699 (18.1)	21 (45.7)	26 (62.9)
Blood pressure lowering medication (%)	828 (28.5)	1325 (34.4)	23 (50)	27 (64.3)
Cholesterol (mmol/L) (mean (SD))	4.99 (1.26)	5.17 (1.18)	4.77 (1.39)	4.95 (1.53)
HDL cholesterol (mmol/L) (mean (SD))	1.3 (0.33)	1.54 (0.36)	1.32 (0.37)	1.38 (0.38)
Person-years of observation (mean (SD))	12.69 (1.8)	12.73 (1.6)	5.48 (2.21)	5.22 (2.41)
Lipid lowering medication (%)	395 (13.6)	462 (12)	13 (28.3)	12 (28.6)

Table 3F. Descriptive Characteristics of the PCE Prospective Cohort and Excluded Participants, Secondary Analysis

	Prospective cohort (N = 6753)		Excluded (N = 1135) *		
	Men	Women	Men	Women	Missing counts
N	2901	3852	425	552	158
Age (years) (Mean (SD))	51.26 (8.13)	51.9 (7.93)	51.99 (8.49)	51.56 (7.97)	
Mean SBP (mmHg) (mean (SD))	136.87 (18.56)	138.12 (18.59)	137.14 (18.4)	137.95 (18.96)	23
Smoking category (%)					26
Current	481 (16.6)	356 (9.2)	68 (16)	70 (12.7)	
Non-current	2420 (83.4)	3496 (90.8)	357 (84)	482 (87.3)	
Type 1 Diabetes (%)	57 (2)	67 (1.7)	8 (1.9)	10 (1.8)	
Type 2 Diabetes (%)	606 (20.1)	699 (18.1)	106 (24.9)	104 (18.8)	
Blood pressure lowering medication (%)	828 (28.5)	1325 (34.4)	152 (35.8)	177 (32.1)	
Cholesterol (mmol/L) (mean (SD))	4.99 (1.26)	5.17 (1.18)	4.9 (1.27)	5.16 (1.15)	504
HDL cholesterol (mmol/L) (mean (SD))	1.3 (0.33)	1.54 (0.36)	1.28 (0.3)	1.54 (0.36)	1058
Person-years of observation (mean (SD))	12.69 (1.8)	12.73 (1.6)	12.16 (3.4)	12.69 (2.11)	
Lipid lowering medication (%)	395 (13.6)	462 (12)	68 (16)	60 (10.9)	

* 158 participants excluded from calculations due to missing variables on gender

Table 4A. Association of Different Polygenic Risk Scores (PRS) With Coronary Artery Disease (CAD) in Tuning Case-Control Study and in Prospective Cohort Study in European GWAS meta-analysis

Methods	P-value/Tuning Parameters	AUC (95% CI) PRS	
		Case-control study (N = 9,499)	Cohort Study (N = 7,036)
Clumping and Thresholding	R ² =0.2, P=0.00000005	0.6179 (0.6137-0.6221)	0.595 (0.5917-0.5982)
Clumping and Thresholding	R ² =0.2, P=0.000005	0.6225 (0.6183-0.6267)	0.5955 (0.5922-0.5987)
Clumping and Thresholding	R ² =0.2, P=0.0005	0.6230 (0.6188-0.6272)	0.5976 (0.5944-0.6009)
Clumping and Thresholding	R ² =0.2, P=0.05	0.6005 (0.5963-0.6047)	0.5835 (0.5802-0.5868)
Clumping and Thresholding	R ² =0.2, P=0.5	0.5966 (0.5924-0.6047)	0.578 (0.5747-0.5813)
Clumping and Thresholding	R ² =0.2, P=1	0.5962 (0.592-0.6004)	0.5777 (0.5744-0.5809)
Clumping and Thresholding	R ² =0.4, P=0.00000005	0.6155 (0.6113-0.6197)	0.593 (0.5897-0.5963)
Clumping and Thresholding	R ² =0.4, P=0.000005	0.6221 (0.6179-0.6263)	0.596 (0.5927-0.5993)
Clumping and Thresholding	R ² =0.4, P=0.0005	0.6291 (0.6249-0.6333)	0.6039 (0.6007-0.6072)
Clumping and Thresholding	R ² =0.4, P=0.05	0.6146 (0.6104-0.6188)	0.5941 (0.5908-0.5974)
Clumping and Thresholding	R ² =0.4, P=0.5	0.61 (0.6058-0.6142)	0.5871 (0.5838-0.5903)
Clumping and Thresholding	R ² =0.4, P=1	0.6094 (0.6052-0.6136)	0.5865 (0.5832-0.5897)
Clumping and Thresholding	R ² =0.6, P=0.00000005	0.6138 (0.6096-0.6180)	0.5911 (0.5878-0.5944)
Clumping and Thresholding	R ² =0.6, P=0.000005	0.6236 (0.6194-0.6278)	0.5982 (0.5949-0.6014)
Clumping and Thresholding	R ² =0.6, P=0.0005	0.6314 (0.6272-0.6356)	0.6043 (0.6010-0.6075)
Clumping and Thresholding	R ² =0.6, P=0.05	0.6230 (0.6188-0.6272)	0.5997 (0.5964-0.603)
Clumping and Thresholding	R ² =0.6, P=0.5	0.6169 (0.6127-0.6211)	0.5924 (0.5892-0.5957)
Clumping and Thresholding	R ² =0.6, P=1	0.6159 (0.6117-0.6201)	0.5918 (0.5885-0.5951)
Clumping and Thresholding	R ² =0.8, P=0.00000005	0.6069 (0.6027-0.6111)	0.5852 (0.5819-0.5983)
Clumping and Thresholding	R ² =0.8, P=0.000005	0.6188 (0.6146-0.6230)	0.5951 (0.5918-0.5983)
Clumping and Thresholding	R ² =0.8, P=0.0005	0.6309 (0.6267-0.6335)	0.6049 (0.6016-0.6082)
Clumping and Thresholding	R ² =0.8, P=0.05	0.6293 (0.6251-0.6335)	0.6056 (0.6023-0.6088)
Clumping and Thresholding	R ² =0.8, P=0.5	0.6226 (0.6184-0.6268)	0.5977 (0.5944-0.6009)
Clumping and Thresholding	R ² =0.8, P=1	0.6217 (0.6175-0.6259)	0.5972 (0.5939-0.6004)
LDpred	p = 0.001	0.5322 (0.4874-0.5769)	0.5198 (0.4806-0.559)
LDpred	p = 0.01	0.5668 (0.5221-0.6115)	0.5225 (0.5133-0.5917)
LDpred	p = 0.1	0.6496 (0.6048-0.6943)	0.6238 (0.5846-0.663)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
LDpred	$p = 1$	0.6356 (0.5909-0.686)	0.6123 (0.5731-0.6515)
LDpred	$p = 0.003$	0.5323 (0.4876-0.577)	0.5222 (0.483-0.5614)
LDpred	$p = 0.03$	0.6585 (0.6138-0.7033)	0.6316 (0.5924-0.6708)
LDpred	$p = 0.3$	0.6413 (0.5966-0.686)	0.6168 (0.5776-0.6560)
lassosum	$s=0.2, \lambda=0.001$	0.5826 (0.5737-0.5916)	0.5681 (0.5602-0.5761)
lassosum	$s=0.2, \lambda=0.0013$	0.5885 (0.5795-0.5974)	0.5732 (0.5652-0.5812)
lassosum	$s=0.2, \lambda=0.0016$	0.5962 (0.5873-0.6052)	0.5818 (0.5738-0.5898)
lassosum	$s=0.2, \lambda=0.0021$	0.6065 (0.5976-0.6155)	0.5905 (0.5825-0.5985)
lassosum	$s=0.2, \lambda=0.0026$	0.6201 (0.6111-0.629)	0.5997 (0.5917-0.6077)
lassosum	$s=0.2, \lambda=0.0034$	0.6346 (0.6257-0.6436)	0.6133 (0.6053-0.6212)
lassosum	$s=0.2, \lambda=0.0043$	0.6487 (0.6397-0.6576)	0.6225 (0.6146-0.6305)
lassosum	$s=0.2, \lambda=0.0055$	0.6458 (0.6369-0.6548)	0.6176 (0.6097-0.6256)
lassosum	$s=0.2, \lambda=0.007$	0.6281 (0.6191-0.637)	0.6043 (0.5963-0.6122)
lassosum	$s=0.2, \lambda=0.0089$	0.6106 (0.6017-0.6196)	0.5903 (0.5824-0.5983)
lassosum	$s=0.2, \lambda=0.0113$	0.5955 (0.5865-0.6045)	0.5778 (0.5698-0.5857)
lassosum	$s=0.2, \lambda=0.0114$	0.5819 (0.573-0.5909)	0.5648 (0.5568-0.5728)
lassosum	$s=0.2, \lambda=0.0183$	0.5714 (0.5624-0.5804)	0.5545 (0.5465-0.5624)
lassosum	$s=0.2, \lambda=0.0234$	0.5655 (0.5566-0.5745)	0.5486 (0.5406-0.5565)
lassosum	$s=0.2, \lambda=0.0298$	0.5577 (0.5488-0.5667)	0.5411 (0.5332-0.5491)
lassosum	$s=0.2, \lambda=0.0379$	0.5569 (0.548-0.5659)	0.541 (0.533-0.549)
lassosum	$s=0.2, \lambda=0.0483$	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	$s=0.2, \lambda=0.0616$	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	$s=0.2, \lambda=0.0785$	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	$s=0.2, \lambda=0.1$	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	$s=0.5, \lambda=0.001$	0.6016 (0.5927-0.6106)	0.5842 (0.5762-0.5921)
lassosum	$s=0.5, \lambda=0.0013$	0.6069 (0.598-0.6159)	0.589 (0.581-0.5969)
lassosum	$s=0.5, \lambda=0.0016$	0.6131 (0.6041-0.6221)	0.5951 (0.5871-0.6031)
lassosum	$s=0.5, \lambda=0.0021$	0.6214 (0.6125-0.6304)	0.6019 (0.594-0.6099)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
lassosum	s=0.5, lambda=0.0026	0.6328 (0.6239-0.6418)	0.6106 (0.6026-0.6185)
lassosum	s=0.5, lambda=0.0034	0.6452 (0.6362-0.6541)	0.6216 (0.6136-0.6296)
lassosum	s=0.5, lambda=0.0043	0.6538 (0.6449-0.6628)	0.626 (0.6181-0.634)
lassosum	s=0.5, lambda=0.0055	0.6454 (0.6364-0.6543)	0.6178 (0.6099-0.6258)
lassosum	s=0.5, lambda=0.007	0.6273 (0.6183-0.6363)	0.6031 (0.5952-0.6111)
lassosum	s=0.5, lambda=0.0089	0.6103 (0.6013-0.6193)	0.5895 (0.5815-0.5974)
lassosum	s=0.5, lambda=0.0113	0.5946 (0.5856-0.6036)	0.5767 (0.5688-0.5847)
lassosum	s=0.5, lambda=0.0114	0.5803 (0.5714-0.5893)	0.5633 (0.5554-0.5713)
lassosum	s=0.5, lambda=0.0183	0.5702 (0.5613-0.5792)	0.5535 (0.5456-0.5615)
lassosum	s=0.5, lambda=0.0234	0.5645 (0.5556-0.5735)	0.5476 (0.5397-0.5556)
lassosum	s=0.5, lambda=0.0298	0.5578 (0.5488-0.5667)	0.5411 (0.5332-0.5491)
lassosum	s=0.5, lambda=0.0379	0.5576 (0.5486-0.5665)	0.5411 (0.5331-0.5491)
lassosum	s=0.5, lambda=0.0483	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.5, lambda=0.0616	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.5, lambda=0.0785	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.5, lambda=0.1	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.9, lambda=0.001	0.6279 (0.619-0.6369)	0.6056 (0.5977-0.6136)
lassosum	s=0.9, lambda=0.0013	0.6322 (0.6232-0.6411)	0.6094 (0.6014-0.6173)
lassosum	s=0.9, lambda=0.0016	0.6375 (0.6285-0.6464)	0.6139 (0.606-0.6219)
lassosum	s=0.9, lambda=0.0021	0.6438 (0.6349-0.6528)	0.6193 (0.6113-0.6272)
lassosum	s=0.9, lambda=0.0026	0.6513 (0.6423-0.6602)	0.6253 (0.6174-0.6333)
lassosum	s=0.9, lambda=0.0034	0.6563 (0.6474-0.6653)	0.6293 (0.6214-0.6373)
lassosum	s=0.9, lambda=0.0043	0.6516 (0.6427-0.6606)	0.6241 (0.6162-0.6321)
lassosum	s=0.9, lambda=0.0055	0.6366 (0.6276-0.6455)	0.611 (0.603-0.6189)
lassosum	s=0.9, lambda=0.007	0.6193 (0.6103-0.6282)	0.5958 (0.5879-0.6038)
lassosum	s=0.9, lambda=0.0089	0.603 (0.5941-0.612)	0.5823 (0.5743-0.5903)
lassosum	s=0.9, lambda=0.0113	0.5884 (0.5794-0.5973)	0.5699 (0.5619-0.5779)
lassosum	s=0.9, lambda=0.0114	0.576 (0.5671-0.585)	0.5579 (0.5499-0.5659)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
lassosum	s=0.9, lambda=0.0183	0.5662 (0.5573-0.5752)	0.5494 (0.5415-0.5574)
lassosum	s=0.9, lambda=0.0234	0.5619 (0.553-0.5709)	0.5448 (0.5368-0.5527)
lassosum	s=0.9, lambda=0.0298	0.558 (0.549-0.5669)	0.5412 (0.5332-0.5491)
lassosum	s=0.9, lambda=0.0379	0.5578 (0.5488-0.5667)	0.5411 (0.5332-0.5491)
lassosum	s=0.9, lambda=0.0483	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.9, lambda=0.0616	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.9, lambda=0.0785	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=0.9, lambda=0.1	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=1, lambda=0.001	0.6221 (0.6132-0.6311)	0.5982 (0.5902-0.6061)
lassosum	s=1, lambda=0.0013	0.6231 (0.6141-0.632)	0.5991 (0.5911-0.607)
lassosum	s=1, lambda=0.0016	0.6239 (0.6149-0.6329)	0.5999 (0.5919-0.6078)
lassosum	s=1, lambda=0.0021	0.6246 (0.6156-0.6335)	0.6002 (0.5922-0.6082)
lassosum	s=1, lambda=0.0026	0.6239 (0.6149-0.6328)	0.5996 (0.5917-0.6076)
lassosum	s=1, lambda=0.0034	0.6186 (0.6096-0.6276)	0.5949 (0.587-0.6029)
lassosum	s=1, lambda=0.0043	0.6086 (0.5996-0.6176)	0.5864 (0.5785-0.5944)
lassosum	s=1, lambda=0.0055	0.5972 (0.5882-0.6061)	0.5776 (0.5697-0.5856)
lassosum	s=1, lambda=0.007	0.5869 (0.5779-0.5958)	0.5691 (0.5612-0.5771)
lassosum	s=1, lambda=0.0089	0.577 (0.5681-0.586)	0.5598 (0.5519-0.5678)
lassosum	s=1, lambda=0.0113	0.571 (0.5621-0.58)	0.5529 (0.545-0.5609)
lassosum	s=1, lambda=0.0114	0.5662 (0.5572-0.5752)	0.5471 (0.5392-0.5551)
lassosum	s=1, lambda=0.0183	0.5606 (0.5516-0.5696)	0.5427 (0.5348-0.5507)
lassosum	s=1, lambda=0.0234	0.5593 (0.5503-0.5683)	0.5418 (0.5339-0.5498)
lassosum	s=1, lambda=0.0298	0.5584 (0.5494-0.5674)	0.5412 (0.5332-0.5491)
lassosum	s=1, lambda=0.0379	0.5578 (0.5488-0.5667)	0.5411 (0.5332-0.5491)
lassosum	s=1, lambda=0.0483	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=1, lambda=0.0616	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=1, lambda=0.0785	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)
lassosum	s=1, lambda=0.1	0.5311 (0.5221-0.54)	0.5191 (0.5111-0.527)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
PRS-CS	$\phi = 0.000001$	0.6379 (0.6071-0.6688)	0.6120 (0.5877-0.6363)
PRS-CS	$\phi = 0.0001$	0.6621 (0.6312-0.6929)	0.6315 (0.6072-0.6558)
PRS-CS	$\phi = 0.01$	0.6393 (0.6084-0.6701)	0.6147 (0.5904-0.6390)
PRS-CS	$\phi = 1$	0.6146 (0.5837-0.6454)	0.5942 (0.5698-0.6185)
sBayesR	LD matrix = HapMap3 and 2.8M	0.5359 (0.5297-0.5421)	0.5227(0.5053-0.5400)
sBayesR	LD matrix = 2.8M variants	0.5349 (0.5287-0.5411)	0.5199 (0.5026-0.5373)
LDpred-funct	Baseline-LD model with 75 annotations	0.6460 (0.64-0.652)	0.6215 (0.6155 - 0.6275)
DBSLMM	$h^2_f = 0.8$	0.5326 (0.5266-0.5386)	0.5236 (0.5176-0.5296)
DBSLMM	$h^2_f = 1$	0.5326 (0.5266-0.5386)	0.5236 (0.5176-0.5296)
DBSLMM	$h^2_f = 1.2$	0.5326 (0.5266-0.5386)	0.5236 (0.5176-0.5296)

Table 4B. Association of Different Polygenic Risk Scores (PRS) With Coronary Artery Disease (CAD) in Tuning Case-Control Study and in Prospective Cohort Study in Japan Biobank dataset

		AUC (95% CI) PRS	
Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
Clumping and Thresholding	R2=0.02, P=0.00000005	0.549 (0.5454-0.5526)	0.5341 (0.5312-0.5371)
Clumping and Thresholding	R2=0.02, P=0.000005	0.5529 (0.5494-0.5565)	0.5395 (0.5365-0.5424)
Clumping and Thresholding	R2=0.02, P=0.0005	0.5602 (0.5567-0.5638)	0.5488 (0.5458-0.5517)
Clumping and Thresholding	R2=0.02, P=0.05	0.5584 (0.5548-0.5619)	0.542 (0.5391-0.545)
Clumping and Thresholding	R2=0.02, P=0.5	0.5559 (0.5523-0.5595)	0.5401 (0.5372-0.5431)
Clumping and Thresholding	R2=0.02, P=1	0.5558 (0.5522-0.5594)	0.5394 (0.5364-0.5423)
Clumping and Thresholding	R2=0.04, P=0.00000005	0.5492 (0.5456-0.5527)	0.5331 (0.5301-0.536)
Clumping and Thresholding	R2=0.04, P=0.000005	0.5515 (0.5479-0.5551)	0.5372 (0.5343-0.5402)
Clumping and Thresholding	R2=0.04, P=0.0005	0.558 (0.5545-0.5616)	0.5472 (0.5443-0.5501)
Clumping and Thresholding	R2=0.04, P=0.05	0.567 (0.5634-0.5706)	0.5489 (0.546-0.5519)
Clumping and Thresholding	R2=0.04, P=0.5	0.5647 (0.5611-0.5638)	0.5448 (0.5418-0.5477)
Clumping and Thresholding	R2=0.04, P=1	0.5639 (0.5604-0.5675)	0.5444 (0.5414-0.5477)
Clumping and Thresholding	R2=0.06, P=0.00000005	0.5471 (0.5435-0.5507)	0.532 (0.5291-0.5349)
Clumping and Thresholding	R2=0.06, P=0.000005	0.5471 (0.5435-0.5507)	0.532 (0.5291-0.5349)
Clumping and Thresholding	R2=0.06, P=0.0005	0.5522 (0.5486-0.5558)	0.543 (0.54-0.5459)
Clumping and Thresholding	R2=0.06, P=0.05	0.5671 (0.5635-0.5707)	0.5523 (0.5494-0.5553)
Clumping and Thresholding	R2=0.06, P=0.5	0.5683 (0.5647-0.5719)	0.5488 (0.5458-0.5517)
Clumping and Thresholding	R2=0.06, P=1	0.5679 (0.5643-0.5715)	0.548 (0.5451-0.551)
Clumping and Thresholding	R2=0.08, P=0.00000005	0.5495 (0.5459-0.5531)	0.5339 (0.531-0.5369)
Clumping and Thresholding	R2=0.08, P=0.000005	0.5457 (0.5421-0.5493)	0.5347 (0.5318-0.5377)
Clumping and Thresholding	R2=0.08, P=0.0005	0.551 (0.5474-0.5546)	0.542 (0.539-0.5449)
Clumping and Thresholding	R2=0.08, P=0.05	0.567 (0.5634-0.5706)	0.5551 (0.5522-0.5581)
Clumping and Thresholding	R2=0.08, P=0.5	0.5712 (0.5676-0.5748)	0.552 (0.5491-0.5549)
Clumping and Thresholding	R2=0.08, P=1	0.5709 (0.5673-0.5745)	0.5512 (0.5483-0.5542)
LDpred	p = 0.001	0.5313 (0.508-0.5543)	0.5185 (0.4994-0.5376)
LDpred	p = 0.01	0.5327 (0.5096-0.5559)	0.5181 (0.499-0.5372)
LDpred	p = 0.1	0.593 (0.5698-0.6161)	0.569 (0.5499-0.5881)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
LDpred	p = 1	0.582 (0.5589-0.6052)	0.56 (0.5409-0.5791)
LDpred	p = 0.003	0.5311 (0.5079-0.5542)	0.5192 (0.5001-0.5383)
LDpred	p = 0.03	0.5446 (0.5214-0.5677)	0.5286 (0.5095-0.5477)
LDpred	p = 0.3	0.586 (0.5628-0.6091)	0.5634 (0.5443-0.5825)
lassosum	s=0.2, lambda=0.001	0.5577 (0.5533-0.5622)	0.5395 (0.5356-0.5434)
lassosum	s=0.2, lambda=0.0013	0.5626 (0.5582-0.5671)	0.543 (0.5391-0.5469)
lassosum	s=0.2, lambda=0.0016	0.5688 (0.5644-0.5733)	0.5472 (0.5433-0.5511)
lassosum	s=0.2, lambda=0.0021	0.5752 (0.5707-0.5796)	0.5519 (0.548-0.5559)
lassosum	s=0.2, lambda=0.0026	0.5798 (0.5754-0.5843)	0.5572 (0.5533-0.5611)
lassosum	s=0.2, lambda=0.0034	0.5837 (0.5793-0.5882)	0.5631 (0.5592-0.567)
lassosum	s=0.2, lambda=0.0043	0.5873 (0.5829-0.5918)	0.5685 (0.5646-0.5724)
lassosum	s=0.2, lambda=0.0055	0.5903 (0.5858-0.5947)	0.5719 (0.5679-0.5758)
lassosum	s=0.2, lambda=0.007	0.5863 (0.5819-0.5908)	0.5676 (0.5637-0.5715)
lassosum	s=0.2, lambda=0.0089	0.5796 (0.5752-0.5841)	0.5596 (0.5557-0.5636)
lassosum	s=0.2, lambda=0.0113	0.5723 (0.5678-0.5767)	0.5525 (0.5486-0.5564)
lassosum	s=0.2, lambda=0.0114	0.5656 (0.5612-0.5701)	0.5464 (0.5424-0.5503)
lassosum	s=0.2, lambda=0.0183	0.5593 (0.5549-0.5638)	0.5412 (0.5373-0.5451)
lassosum	s=0.2, lambda=0.0234	0.5549 (0.5505-0.5594)	0.5387 (0.5348-0.5426)
lassosum	s=0.2, lambda=0.0298	0.5555 (0.551-0.56)	0.54 (0.5361-0.5439)
lassosum	s=0.2, lambda=0.0379	0.5562 (0.5518-0.5607)	0.54 (0.536-0.5439)
lassosum	s=0.2, lambda=0.0483	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.2, lambda=0.0616	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.2, lambda=0.0785	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.2, lambda=0.1	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.5, lambda=0.001	0.5684 (0.564-0.5729)	0.5491 (0.5452-0.553)
lassosum	s=0.5, lambda=0.0013	0.5724 (0.568-0.5769)	0.5519 (0.548-0.5558)
lassosum	s=0.5, lambda=0.0016	0.5772 (0.5728-0.5817)	0.5552 (0.5513-0.5592)
lassosum	s=0.5, lambda=0.0021	0.5818 (0.5773-0.5862)	0.5592 (0.5553-0.5631)
lassosum	s=0.5, lambda=0.0026	0.5853 (0.5809-0.5898)	0.5636 (0.5597-0.5675)
lassosum	s=0.5, lambda=0.0034	0.5887 (0.5843-0.5932)	0.569 (0.565-0.5729)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
lassosum	s=0.5, lambda=0.0043	0.5921 (0.5876-0.5965)	0.5736 (0.5697-0.5775)
lassosum	s=0.5, lambda=0.0055	0.594 (0.5895-0.5985)	0.5749 (0.571-0.5788)
lassosum	s=0.5, lambda=0.007	0.5886 (0.5841-0.5931)	0.5689 (0.565-0.5728)
lassosum	s=0.5, lambda=0.0089	0.5802 (0.5758-0.5847)	0.5601 (0.5562-0.564)
lassosum	s=0.5, lambda=0.0113	0.5729 (0.5685-0.5774)	0.5527 (0.5488-0.5566)
lassosum	s=0.5, lambda=0.0114	0.5663 (0.5618-0.5707)	0.5469 (0.5429-0.5508)
lassosum	s=0.5, lambda=0.0183	0.5603 (0.5558-0.5647)	0.5416 (0.5377-0.5455)
lassosum	s=0.5, lambda=0.0234	0.5556 (0.5512-0.5601)	0.539 (0.5351-0.5429)
lassosum	s=0.5, lambda=0.0298	0.5566 (0.5521-0.561)	0.5406 (0.5367-0.5446)
lassosum	s=0.5, lambda=0.0379	0.5563 (0.5518-0.5607)	0.5399 (0.536-0.5438)
lassosum	s=0.5, lambda=0.0483	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.5, lambda=0.0616	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.5, lambda=0.0785	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.5, lambda=0.1	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.9, lambda=0.001	0.5806 (0.5761-0.585)	0.5611 (0.5572-0.565)
lassosum	s=0.9, lambda=0.0013	0.5832 (0.5787-0.5876)	0.5631 (0.5592-0.567)
lassosum	s=0.9, lambda=0.0016	0.5859 (0.5815-0.5904)	0.5653 (0.5614-0.5692)
lassosum	s=0.9, lambda=0.0021	0.5884 (0.5839-0.5929)	0.5682 (0.5642-0.5721)
lassosum	s=0.9, lambda=0.0026	0.591 (0.5866-0.5955)	0.5716 (0.5677-0.5755)
lassosum	s=0.9, lambda=0.0034	0.5931 (0.5887-0.5976)	0.5752 (0.5713-0.5792)
lassosum	s=0.9, lambda=0.0043	0.5944 (0.5899-0.5988)	0.5777 (0.5738-0.5816)
lassosum	s=0.9, lambda=0.0055	0.5923 (0.5879-0.5968)	0.5748 (0.5709-0.5787)
lassosum	s=0.9, lambda=0.007	0.5853 (0.5808-0.5898)	0.5654 (0.5614-0.5693)
lassosum	s=0.9, lambda=0.0089	0.5771 (0.5727-0.5816)	0.5568 (0.5528-0.5607)
lassosum	s=0.9, lambda=0.0113	0.5707 (0.5662-0.5751)	0.5501 (0.5462-0.554)
lassosum	s=0.9, lambda=0.0114	0.5656 (0.5612-0.5701)	0.546 (0.5421-0.5499)
lassosum	s=0.9, lambda=0.0183	0.559 (0.5545-0.5634)	0.5405 (0.5366-0.5445)
lassosum	s=0.9, lambda=0.0234	0.5558 (0.5513-0.5602)	0.5384 (0.5345-0.5423)
lassosum	s=0.9, lambda=0.0298	0.5578 (0.5533-0.5623)	0.5405 (0.5366-0.5444)
lassosum	s=0.9, lambda=0.0379	0.5563 (0.5518-0.5608)	0.5398 (0.5359-0.5438)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
lassosum	s=0.9, lambda=0.0483	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.9, lambda=0.0616	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.9, lambda=0.0785	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=0.9, lambda=0.1	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=1, lambda=0.001	0.5723 (0.5678-0.5767)	0.5572 (0.5533-0.5612)
lassosum	s=1, lambda=0.0013	0.5723 (0.5678-0.5768)	0.5576 (0.5537-0.5615)
lassosum	s=1, lambda=0.0016	0.5721 (0.5676-0.5765)	0.5579 (0.554-0.5618)
lassosum	s=1, lambda=0.0021	0.5713 (0.5669-0.5758)	0.5578 (0.5539-0.5617)
lassosum	s=1, lambda=0.0026	0.5697 (0.5653-0.5742)	0.5569 (0.5529-0.5608)
lassosum	s=1, lambda=0.0034	0.5672 (0.5628-0.5717)	0.5548 (0.5508-0.5587)
lassosum	s=1, lambda=0.0043	0.5639 (0.5595-0.5684)	0.5511 (0.5472-0.5551)
lassosum	s=1, lambda=0.0055	0.5599 (0.5554-0.5643)	0.5464 (0.5425-0.5503)
lassosum	s=1, lambda=0.007	0.557 (0.5525-0.5614)	0.5421 (0.5382-0.546)
lassosum	s=1, lambda=0.0089	0.5559 (0.5515-0.5604)	0.5392 (0.5353-0.5431)
lassosum	s=1, lambda=0.0113	0.5574 (0.5529-0.5618)	0.5379 (0.534-0.5418)
lassosum	s=1, lambda=0.0114	0.5577 (0.5532-0.5621)	0.5373 (0.5333-0.5412)
lassosum	s=1, lambda=0.0183	0.5552 (0.5507-0.5596)	0.5374 (0.5335-0.5413)
lassosum	s=1, lambda=0.0234	0.5513 (0.5469-0.5558)	0.5343 (0.5304-0.5383)
lassosum	s=1, lambda=0.0298	0.5553 (0.5509-0.5598)	0.5379 (0.534-0.5418)
lassosum	s=1, lambda=0.0379	0.5566 (0.5521-0.5611)	0.54 (0.5361-0.544)
lassosum	s=1, lambda=0.0483	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=1, lambda=0.0616	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=1, lambda=0.0785	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
lassosum	s=1, lambda=0.1	0.5311 (0.5266-0.5355)	0.5191 (0.5152-0.523)
PRS-CS	phi = 0.000001	0.583 (0.5619-0.604)	0.5602 (0.5415-0.5788)
PRS-CS	phi =0.0001	0.597 (0.576-0.6181)	0.5752 (0.5565-0.5939)
PRS-CS	phi = 0.01	0.5811 (0.5601-0.6022)	0.5589 (0.5403-0.5776)
PRS-CS	phi = 1	0.5647 (0.5436-0.5858)	0.5466 (0.5279-0.5652)
sBayesR	LD matrix = HapMap3 and 2.8M	0.5308 (0.5248-0.5368)	0.5186 (0.5126-0.5246)
sBayesR	LD matrix = 2.8M variants	0.5328 (0.5268-0.5388)	0.5177 (0.5117-0.5237)

Methods	P-value/Tuning Parameters	Case-control study (N = 9,499)	Cohort Study (N = 7,036)
LDpred-funct	Baseline-LD model with 75 annotations	0.5907 (0.5847-0.5967)	0.5692 (0.5632-0.5752)
DBSLMM	$h^2_f = 0.8$	0.5347 (0.5314-0.5381)	0.5258 (0.5201-0.5314)
DBSLMM	$h^2_f = 1$	0.5353 (0.5319-0.5386)	0.5263 (0.5207-0.532)
DBSLMM	$h^2_f = 1.2$	0.5358 (0.5324-0.5391)	0.5268 (0.5212-0.5324)

Table 5A. C Statistics (Derived for Cox Regression) for CAD Using Recalibrated Models in the PCE Prospective Cohort, Primary Analysis. Results are shown for the European meta-analysis and Japan Biobank datasets. Results are presented for the full population and stratified by gender and age group (below or above 55 years of age). Results for the sensitivity analysis using only participants with no reported lipid-lowering treatment at baseline also shown.

A. European Meta-Analysis						
	All Participants (N=272,307; 7,036 cases)	Men (N=124,155; 5093 cases)	Women (N=148,152; 1,943 cases)	< 55 years old (N=102,330; 1,276 cases)	≥ 55 years old (N=169,977; 5,760 cases)	Participants Not Receiving Lipid- Lowering Treatment at Baseline (N= 235,172; 5,091 cases)
PRS	0.636 (0.63-0.642)	0.639 (0.632-0.647)	0.638 (0.625-0.65)	0.683 (0.669-0.698)	0.629 (0.622-0.636)	0.642 (0.634-0.649)
PCE	0.718 (0.713-0.723)	0.663 (0.656-0.67)	0.706 (0.695-0.717)	0.749 (0.736-0.761)	0.665 (0.658-0.671)	0.73 (0.724-0.737)
PRS + PCE	0.752 (0.746-0.757)	0.712 (0.705-0.718)	0.74 (0.729-0.75)	0.791 (0.779-0.803)	0.704 (0.698-0.71)	0.764 (0.758-0.77)
B. Japan Biobank Dataset						
	All Participants (N=272,307; 7,036 cases)	Men (N=124,155; 5093 cases)	Women (N=148,152; 1,943 cases)	< 55 years old (N=102,330; 1,276 cases)	≥ 55 years old (N=169,977; 5,760 cases)	Participants Not Receiving Lipid- Lowering Treatment at Baseline (N= 235,172; 5,091 cases)
PRS	0.582 (0.576-0.589)	0.582 (0.575-0.59)	0.584 (0.572-0.597)	0.625 (0.61-0.64)	0.576 (0.568-0.583)	0.583 (0.575-0.591)
PCE	0.718 (0.713-0.723)	0.663 (0.656-0.67)	0.706 (0.695-0.717)	0.749 (0.736-0.761)	0.665 (0.658-0.671)	0.73 (0.724-0.737)
PRS + PCE	0.73 (0.725-0.735)	0.681 (0.675-0.688)	0.718 (0.707-0.729)	0.767 (0.755-0.78)	0.678 (0.671-0.684)	0.743 (0.737-0.749)

Table 5B. C Statistics (Derived from Cox Regression) for CAD Using European Meta-analysis dataset and Recalibrated Models in the PCE Prospective Cohort, Primary Analysis. Results are presented for full population and stratified by gender and age group (below or above 55 years of age). Results for the sensitivity analysis using only participants with no reported lipid-lowering treatment at baseline also shown.

A. Full Population (N=272,307; 7036 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.603 (0.597-0.61)	0.63 (0.624-0.636)	0.628 (0.621-0.634)	0.63 (0.624-0.636)	0.603 (0.597-0.61)	0.62 (0.614-0.627)	0.523 (0.517-0.53)
PCE	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)
PRS + PCE	0.738 (0.732-0.743)	0.749 (0.743-0.754)	0.748 (0.743-0.753)	0.749 (0.744-0.754)	0.738 (0.732-0.743)	0.743 (0.738-0.749)	0.718 (0.713-0.724)
B. Men (N=124,155; 5093 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.606 (0.599-0.614)	0.632 (0.624-0.639)	0.63 (0.623-0.638)	0.633 (0.625-0.64)	0.606 (0.599-0.614)	0.621 (0.613-0.628)	0.515 (0.507-0.523)
PCE	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)
PRS + PCE	0.688 (0.681-0.695)	0.703 (0.697-0.71)	0.703 (0.697-0.71)	0.704 (0.697-0.711)	0.688 (0.681-0.695)	0.696 (0.69-0.703)	0.661 (0.654-0.668)
C. Women (N=148,152; 1943 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.602 (0.589-0.614)	0.632 (0.619-0.644)	0.622 (0.609-0.635)	0.629 (0.617-0.642)	0.602 (0.589-0.614)	0.622 (0.61-0.635)	0.527 (0.514-0.54)
PCE	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)
PRS + PCE	0.725 (0.714-0.735)	0.736 (0.726-0.747)	0.732 (0.722-0.743)	0.736 (0.726-0.747)	0.725 (0.714-0.735)	0.731 (0.72-0.742)	0.705 (0.695-0.716)
D. Aged < 55 years old (N=102,330; 1276 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.64 (0.625-0.656)	0.675 (0.66-0.69)	0.67 (0.655-0.685)	0.675 (0.66-0.69)	0.64 (0.625-0.656)	0.662 (0.647-0.677)	0.541 (0.525-0.557)
PCE	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)
PRS + PCE	0.77 (0.757-0.782)	0.783 (0.771-0.795)	0.783 (0.77-0.795)	0.784 (0.772-0.796)	0.77 (0.757-0.782)	0.779 (0.767-0.792)	0.747 (0.734-0.76)
E. Aged ≥ 55 years old (N=169,977; 5,760 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.599 (0.592-0.606)	0.623 (0.616-0.63)	0.621 (0.614-0.629)	0.623 (0.616-0.63)	0.599 (0.592-0.606)	0.614 (0.607-0.621)	0.522 (0.515-0.53)
PCE	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)
PRS + PCE	0.685 (0.679-0.692)	0.698 (0.692-0.704)	0.697 (0.691-0.703)	0.698 (0.692-0.705)	0.685 (0.679-0.692)	0.692 (0.685-0.698)	0.664 (0.658-0.671)
F. Participants not receiving lipid-lowering treatment at baseline (N=235,172; 5,091 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.598 (0.59-0.606)	0.629 (0.621-0.636)	0.627 (0.619-0.634)	0.63 (0.622-0.637)	0.517 (0.509-0.525)	0.623 (0.616-0.631)	0.521 (0.513-0.529)
PCE	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)
PRS + PCE	0.746 (0.74-0.752)	0.758 (0.752-0.764)	0.757 (0.751-0.763)	0.759 (0.753-0.765)	0.73 (0.724-0.736)	0.755 (0.749-0.761)	0.73 (0.723-0.736)

Table 5C. C Statistics (Derived from Cox Regression) for CAD Using Japan Biobank dataset and Recalibrated Models in the PCE Prospective Cohort, Primary Analysis. Results are presented for full population and stratified by gender and age group (below or above 55 years of age). Results for the sensitivity analysis using only participants with no reported lipid-lowering treatment at baseline also shown.

A. Full Population (N=272,307; 7036 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.552 (0.545-0.558)	0.568 (0.562-0.575)	0.577 (0.57-0.583)	0.574 (0.568-0.581)	0.552 (0.545-0.558)	0.569 (0.562-0.575)	0.527 (0.52-0.533)
PCE	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)	0.718 (0.713-0.723)
PRS + PCE	0.722 (0.717-0.727)	0.726 (0.72-0.731)	0.727 (0.721-0.732)	0.727 (0.722-0.733)	0.722 (0.717-0.727)	0.726 (0.721-0.732)	0.718 (0.713-0.724)
B. Men (N=124,155; 5093 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.548 (0.54-0.556)	0.566 (0.558-0.574)	0.578 (0.571-0.586)	0.573 (0.566-0.581)	0.548 (0.54-0.556)	0.565 (0.558-0.573)	0.519 (0.511-0.527)
PCE	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)	0.663 (0.656-0.67)
PRS + PCE	0.666 (0.659-0.673)	0.671 (0.664-0.678)	0.675 (0.668-0.682)	0.674 (0.667-0.681)	0.666 (0.659-0.673)	0.671 (0.665-0.678)	0.66 (0.653-0.667)
C. Women (N=148,152; 1943 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.553 (0.54-0.566)	0.571 (0.559-0.584)	0.571 (0.559-0.584)	0.575 (0.562-0.588)	0.553 (0.54-0.566)	0.574 (0.562-0.587)	0.524 (0.511-0.538)
PCE	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)	0.706 (0.695-0.717)
PRS + PCE	0.707 (0.697-0.718)	0.713 (0.702-0.723)	0.712 (0.701-0.723)	0.714 (0.703-0.724)	0.707 (0.697-0.718)	0.714 (0.704-0.725)	0.705 (0.694-0.716)
D. Aged < 55 years old (N=102,330; 1276 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.586 (0.571-0.602)	0.605 (0.589-0.62)	0.618 (0.603-0.633)	0.616 (0.601-0.632)	0.586 (0.571-0.602)	0.606 (0.591-0.622)	0.55 (0.534-0.566)
PCE	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)	0.749 (0.736-0.761)
PRS + PCE	0.755 (0.742-0.768)	0.758 (0.745-0.77)	0.762 (0.75-0.775)	0.762 (0.75-0.775)	0.755 (0.742-0.768)	0.759 (0.747-0.772)	0.748 (0.735-0.76)
E. Aged ≥ 55 years old (N=169,977; 5,760 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.544 (0.537-0.552)	0.562 (0.555-0.569)	0.567 (0.56-0.574)	0.567 (0.56-0.574)	0.544 (0.537-0.552)	0.562 (0.554-0.569)	0.526 (0.518-0.533)
PCE	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)	0.665 (0.658-0.671)
PRS + PCE	0.667 (0.66-0.674)	0.671 (0.664-0.678)	0.672 (0.666-0.679)	0.673 (0.666-0.679)	0.667 (0.66-0.674)	0.672 (0.665-0.678)	0.664 (0.658-0.671)
F. Participants not receiving lipid-lowering treatment at baseline (N=235,172; 5,091 cases)							
	Clumping and Thresholding	LDpred	lassosum	PRS-CS	sBayesR	LDpred-funct	DBSLMM
PRS	0.549 (0.542-0.557)	0.566 (0.559-0.574)	0.569 (0.562-0.577)	0.572 (0.564-0.58)	0.515 (0.507-0.523)	0.566 (0.558-0.574)	0.525 (0.517-0.533)
PCE	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)	0.73 (0.724-0.737)
PRS + PCE	0.734 (0.727-0.74)	0.738 (0.731-0.744)	0.739 (0.733-0.745)	0.739 (0.733-0.745)	0.729 (0.723-0.735)	0.738 (0.732-0.744)	0.73 (0.724-0.736)

Table 5D. C Statistics (Derived for Cox Regression) for CAD Using Recalibrated Models in the PCE Prospective Cohort, Secondary Analysis. Results are shown for the European meta-analysis and Japan Biobank datasets. Results are presented for the full population and stratified by gender and age group (below or above 55 years of age). Results for the sensitivity analysis using only participants with no reported lipid-lowering treatment at baseline also shown.

A. European Meta-Analysis						
	All Participants (N= 6,753; 88 cases)	Men (N= 2,901; 46 cases)	Women (N= 3,852; 42 cases)	< 55 years old (N=4,528; 42 cases)	≥ 55 years old (N=2,225; 46 cases)	Participants Not Receiving Lipid-Lowering Treatment at Baseline (N= 5,896; 63 cases)
PRS	0.545 (0.488-0.564)	0.572 (0.49-0.653)	0.6 (0.512-0.688)	0.549 (0.461-0.637)	0.551 (0.472-0.63)	0.54 (0.471-0.609)
PCE	0.714 (0.659-0.769)	0.674 (0.595-0.753)	0.734 (0.653-0.815)	0.657 (0.572-0.742)	0.721 (0.656-0.787)	0.698 (0.628-0.768)
PRS + PCE	0.715 (0.662-0.768)	0.708 (0.636-0.78)	0.734 (0.657-0.811)	0.671 (0.587-0.755)	0.7 (0.634-0.767)	0.71 (0.643-0.777)
B. Japan Biobank Dataset						
	All Participants (N= 6,753; 88 cases)	Men (N= 2,901; 46 cases)	Women (N= 3,852; 42 cases)	< 55 years old (N=4,528; 42 cases)	≥ 55 years old (N=2,225; 46 cases)	Participants Not Receiving Lipid-Lowering Treatment at Baseline (N= 5,896; 63 cases)
PRS	0.533 (0.472-0.595)	0.497 (0.409-0.585)	0.549 (0.463-0.634)	0.551 (0.463-0.639)	0.506 (0.417-0.595)	0.522 (0.452-0.591)
PCE	0.714 (0.659-0.769)	0.674 (0.595-0.753)	0.734 (0.653-0.815)	0.657 (0.572-0.742)	0.721 (0.656-0.787)	0.698 (0.628-0.768)
PRS + PCE	0.714 (0.66-0.769)	0.668 (0.589-0.748)	0.735 (0.653-0.816)	0.666 (0.582-0.75)	0.719 (0.653-0.785)	0.697 (0.627-0.767)

Table 6. Risk Reclassification at 7.5% Threshold for CAD Using Recalibrated PCE and PCE + PRS Models Stratified by Gender and Age Group (below or above 55 years of age)

Men							
		PCE + PRS					
		< 7.5% ≥ 7.5%		% reclassified	Categorical NRI:	Continuous NRI:	
PCE	< 7.5%	Cases	2881	1129	22.3	0.1671 (0.1532 to 0.1762)	0.238 (0.2131 to 0.2599)
	≥ 7.5%	Cases	281	783	5.5		
	< 7.5%	Noncases	92944	10405	9.1	-0.051 (-0.056 to -0.047)	0.1722 (0.1634 to 0.1849)
	≥ 7.5%	Noncases	4517	5894	4.0		
NRI in full population:					0.1161 (0.1046 to 0.124)	0.4102 (0.377 to 0.4448)	
IDI:		0.0708 (0.0674 to 0.0743)					
Women							
		PCE + PRS					
		< 7.5% ≥ 7.5%		% reclassified	Categorical NRI:	Continuous NRI:	
PCE	< 7.5%	Cases	1803	88	4.6	0.0413 (0.0302 to 0.0497)	0.0962 (0.0837 to 0.1349)
	≥ 7.5%	Cases	10	30	0.5		
	< 7.5%	Noncases	140610	999	0.7	-0.0056 (-0.0066 to -0.0045)	0.3196 (0.3108 to 0.3611)
	≥ 7.5%	Noncases	244	459	0.2		
NRI in full population:					0.0357 (0.0248 to 0.0431)	0.4158 (0.4057 to 0.496)	
IDI:		0.0452 (0.0398 to 0.0507)					
Aged < 55 years old							
		PCE + PRS					
		< 7.5% ≥ 7.5%		% reclassified	Categorical NRI:	Continuous NRI:	
PCE	< 7.5%	Cases	1053	140	11.0	0.0889 (0.0701 to 0.0984)	0.1683 (0.1063 to 0.2012)
	≥ 7.5%	Cases	28	46	2.2		
	< 7.5%	Noncases	97435	1244	1.2	-0.0076 (-0.0088 to -0.0066)	0.3438 (0.2509 to 0.4)
	≥ 7.5%	Noncases	497	401	0.5		
NRI in full population:					0.0813 (0.0626 to 0.0901)	0.5121 (0.3776 to 0.6012)	
IDI:		0.0702 (0.0628 to 0.0776)					
Aged ≥ 55 years old							
		PCE + PRS					
		< 7.5% ≥ 7.5%		% reclassified	Categorical NRI:	Continuous NRI:	
PCE	< 7.5%	Cases	4093	902	15.7	0.123 (0.1192 to 0.1336)	0.1897 (0.1698 to 0.2285)
	≥ 7.5%	Cases	200	543	3.5		
	< 7.5%	Noncases	140310	8769	5.6	-0.0359 (-0.0391 to -0.0344)	0.1617 (0.1569 to 0.1827)
	≥ 7.5%	Noncases	3163	4253	2.0		
NRI in full population:					0.087 (0.0843 to 0.0969)	0.3514 (0.3304 to 0.4112)	
IDI:		0.0605 (0.0572 to 0.0639)					

Table 7. Net Reclassification Improvement and Integrated Discrimination Improvement Results in Secondary Analysis of 6,753 African Ancestry Participants

	No. of Participants	Continuous Net Reclassification Improvement	Categorical Net Reclassification Improvement	Integrated Discrimination Improvement
Cases	88	0.044 (0.036 to 0.052)	0.0 (-0.46 to 0.0)	
Noncases	6514	-0.046 (-0.054 to -0.038)	0.0 (0.0 to 0.005)	
Full Population	6602	-0.002 (-0.203 to 0.198)	0.0 (-0.041 to 0.001)	0.0129 (-0.0076 to -0.0333)
Censored	151			

Figure 1. Correlation of PRSs Constructed by Different Methods in the Tuning Set of 9,499 Prevalent CAD cases and an Equal Number of Controls.
Abbreviations: PT and LDpredfun refer to the Clumping and Thresholding and LDpred-funct methods, respectively.




Figure 2. Calibration and Recalibration Plots Polygenic Risk Score for Coronary Artery Disease (CAD) and PRS Combined with PCE, Using a UK Biobank Prospective Cohort Sample. Model performance shown for non-recalibrated and recalibrated models. Recalibration was performed by fitting the predicted log hazard of the original models as a covariate in a Cox survival model. P_{GND} is the associated Greenwood-Nam-D'Agostino test P-value that tests a null hypothesis of the observed and expected probabilities being identical in each group.

